Product image of Mitomicin Medac (Mitomycin) supplied by GNH India

Mitomicin Medac

Active Ingredient:
Mitomycin
Origin:
EU

Mitomicin Medac (Mitomycin)

Mitomycin, the active ingredient in Mitomicin Medac, is an alkylating agent presented as an injectable solution for intravenous and intravesical use. It is employed in the treatment of various solid tumours, including bladder, gastric and pancreatic cancers, and is administered under specialist supervision.

GNH India supplies Mitomicin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mitomicin Medac is an alkylating antineoplastic agent used in several solid‑tumour indications.

  • Bladder cancer (intravesical): provides local cytotoxic activity to reduce tumour recurrence after transurethral resection.
  • Gastric cancer: used as part of combination chemotherapy regimens to improve response rates.
  • Pancreatic cancer: incorporated into multi‑drug protocols for advanced disease management.
  • Other solid tumours: employed in selected cases where tumour sensitivity to DNA cross‑linking agents is demonstrated.

How It Works

  • Mitomycin exerts its antineoplastic effect by undergoing enzymatic reduction within hypoxic tumour cells, forming reactive intermediates that create covalent cross‑links between DNA strands. These cross‑links inhibit DNA replication and transcription, ultimately triggering apoptosis and cell death in rapidly proliferating cancer cells.

Side Effects

Mitomicin Medac may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
  • Myelosuppression: reduced white blood cells, red blood cells, and platelets.
  • Mucositis: inflammation of the mouth and gastrointestinal lining.
  • Fatigue: generalized tiredness affecting daily activities.
  • Renal toxicity: impaired kidney function, especially with intravesical administration.

Serious or Rare Side Effects

  • Pulmonary fibrosis: progressive scarring of lung tissue.
  • Severe hemorrhage: bleeding complications due to thrombocytopenia.
  • Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity.
  • Secondary malignancies: risk of new cancers developing after treatment.
  • Hepatotoxicity: liver enzyme elevations or dysfunction.

Precautions & Warnings

When using Mitomicin Medac, clinicians should observe several safety measures.

  • Renal function monitoring: assess creatinine clearance before and during therapy.
  • Hematologic assessment: perform regular complete blood counts to detect myelosuppression.
  • Pulmonary evaluation: baseline and periodic lung function tests for patients at risk.
  • Pregnancy risk: avoid use in pregnant women; drug is classified as Category D.
  • Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Avoid Interactions

Mitomicin Medac can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Concurrent nephrotoxic agents: may exacerbate renal impairment.
  • Strong CYP450 inducers: could reduce mitomycin efficacy.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: increased bleeding risk due to thrombocytopenia.
  • Other myelosuppressive chemotherapy: heightened bone‑marrow suppression.
  • Radiotherapy: potential for enhanced tissue toxicity when combined.

Frequently Asked Questions

Mitomicin Medac contains mitomycin, an alkylating antineoplastic agent used primarily for bladder cancer administered intravesically, and as part of combination chemotherapy for gastric, pancreatic and other solid tumours. Its use is limited to specialist oncology settings where the benefits outweigh potential risks.

Mitomycin is reduced inside hypoxic tumour cells to generate reactive species that cross‑link DNA strands. This prevents DNA replication and transcription, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells. The drug’s effect is enhanced in low‑oxygen environments typical of many solid tumours.

The dosing regimen for Mitomicin Medac is individualized by the treating oncologist based on tumour type, stage, patient weight, renal function and treatment protocol. Physicians determine the appropriate dose, schedule and route of administration for each patient.

Mitomycin is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy unless absolutely necessary. Breastfeeding is also contraindicated because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other alkylating agents such as cyclophosphamide, mitomycin has a unique activation pathway that requires enzymatic reduction in hypoxic cells, offering selective toxicity for certain solid tumours. Its intravesical formulation provides a localized option for bladder cancer that many systemic agents cannot match.

Mitomicin Medac should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Follow standard aseptic handling procedures for injectable medicines to maintain sterility.

The drug is supplied as a sterile injectable solution for intravenous infusion or intravesical instillation. Intravenous dosing is performed by a qualified healthcare professional in a controlled setting, while intravesical therapy involves catheter‑based delivery directly into the bladder, usually after tumour resection.

Serious risks include severe myelosuppression leading to infection or bleeding, pulmonary fibrosis, renal toxicity, and rare but life‑threatening anaphylactic reactions. Continuous monitoring of blood counts, renal function and respiratory status is essential throughout treatment.

Patients with known hypersensitivity to mitomycin, severe renal impairment, uncontrolled infections, or those who are pregnant should not receive Mitomicin Medac. Additionally, individuals with pre‑existing pulmonary fibrosis or significant bone‑marrow failure are contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mitomycin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT